Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 12Unknown 6Recruiting 6Completed 2Terminated 1

Sponsor Class

INDUSTRY 39OTHER 26OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Mid-low Rectal Cancer 1Immunotherapy 1

Interventions

Gemcitabine 15Cisplatin 12Radiotherapy 11Metformin 8Fluorouracil 8Capecitabine 8Paclitaxel 7Oxaliplatin 7Exercise 7Indocyanine Green 6Docetaxel 6Cyclophosphamide 6Control Groups 6Surveys and Questionnaires 5Standard of Care 5Nivolumab 5Letrozole 5Irinotecan 5pembrolizumab 4durvalumab 4Zoledronic Acid 4Vinorelbine 4Saline Solution 4Preoperative Exercise 4Magnetic Resonance Spectroscopy 4Leucovorin 4Ifosfamide 4Gefitinib 4Drug Therapy 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × OTHER_GOV × tislelizumab × Clear all
NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Completed
38 enrolled
Gastrointestinal

Mid-low Rectal Cancer

NCT05223088 2025-03-18

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Fujian Cancer Hospital

Phase 2 Completed
40 enrolled
Gastrointestinal

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡